FDA Inspection 1224257 — Nexus Pharmaceuticals, LLC
The FDA completed an inspection of Nexus Pharmaceuticals, LLC on Nov 7, 2023 in Lincolnshire, IL. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Nov 7, 2023
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Lincolnshire, IL (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)